PHARMACOLOGICAL CARDIAC PROTECTION: WHAT IS NEW?
The lecture is devoted to the current state of pharmacological cardiac protection in patients with a high cardiac risk undergoing non-cardiac and cardiac surgery with cardiopulmonary bypass. It describes the main etiopathogenetic mechanisms of ischemic reperfusion myocardial damage. The possible car...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
NEW TERRA Publishing House
2019-05-01
|
| Series: | Вестник анестезиологии и реаниматологии |
| Subjects: | |
| Online Access: | https://www.vair-journal.com/jour/article/view/321 |
| Summary: | The lecture is devoted to the current state of pharmacological cardiac protection in patients with a high cardiac risk undergoing non-cardiac and cardiac surgery with cardiopulmonary bypass. It describes the main etiopathogenetic mechanisms of ischemic reperfusion myocardial damage. The possible cardioprotection mechanisms when using inhalation anesthetics, β-adrenoreceptor blocking agents, calcium channel blockers, statins, nitrates, α2 -agonists, ACE inhibitors and sartans, levosimendan, phosphocreatine, and glucose-insulin-potassium mixture are analyzed. New research data are reviewed, including recent meta-analyses and extensive randomized studies aimed to assess the efficacy of the above medicines. It presents contemporary clinical guidelines on the use of pharmacological cardioprotection in various clinical situations. It has been concluded that the range of drugs recommended for cardioprotection is constantly changing in accordance with latest data, and updating the scientific information on this issue is an important to improve the professional competence of anesthesiologists and emergency physicians. |
|---|---|
| ISSN: | 2078-5658 2541-8653 |